These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36213210)

  • 1. Investigation of potential substandard dry powder inhalers on EU and North African markets - evaluation of the delivered and fine particle doses.
    Zhang Y; Hubert P; Hubert C
    J Drug Assess; 2022; 11(1):20-25. PubMed ID: 36213210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of capsule type on aerodynamic performance of inhalation products: A case study using a formoterol-lactose binary or ternary blend.
    Wauthoz N; Hennia I; Ecenarro S; Amighi K
    Int J Pharm; 2018 Dec; 553(1-2):47-56. PubMed ID: 30321640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers.
    Buttini F; Brambilla G; Copelli D; Sisti V; Balducci AG; Bettini R; Pasquali I
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):167-78. PubMed ID: 26355743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
    Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
    Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistent Dosing Through the Salmeterol-Fluticasone Propionate Easyhaler for the Management of Asthma and Chronic Obstructive Pulmonary Disease: Robustness Analysis Across the Easyhaler Lifetime.
    Turpeinen A; Eriksson P; Happonen A; Husman-Piirainen J; Haikarainen J
    J Aerosol Med Pulm Drug Deliv; 2021 Jun; 34(3):189-196. PubMed ID: 32960127
    [No Abstract]   [Full Text] [Related]  

  • 6. Equivalence testing of salbutamol dry powder inhalers: in vitro impaction results versus in vivo efficacy.
    Weda M; Zanen P; de Boer AH; Gjaltema D; Ajaoud A; Barends DM; Frijlink HW
    Int J Pharm; 2002 Dec; 249(1-2):247-55. PubMed ID: 12433452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aerosol electrostatics. I: Properties of fine powders before and after aerosolization by dry powder inhalers.
    Byron PR; Peart J; Staniforth JN
    Pharm Res; 1997 Jun; 14(6):698-705. PubMed ID: 9210184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study.
    Janson C; Lööf T; Telg G; Stratelis G; Nilsson F
    NPJ Prim Care Respir Med; 2016 Nov; 26():16053. PubMed ID: 27853177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical equivalence of the combination formulation of budesonide and formoterol in a single capsule with a dry powder inhaler.
    Andrade-Lima M; Pereira LF; Fernandes AL
    J Bras Pneumol; 2012; 38(6):748-56. PubMed ID: 23288120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Pierce and inhale" design in capsule based dry powder inhalers: Effect of capsule piercing and motion on aerodynamic performance of drugs.
    Martinelli F; Balducci AG; Rossi A; Sonvico F; Colombo P; Buttini F
    Int J Pharm; 2015 Jun; 487(1-2):197-204. PubMed ID: 25843756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formoterol dry-powder inhalation--Novartis/SkyePharma: Foradil MDDPI, Foradil MDPI, Foradil SkyeHaler, formoterol fumarate dry-powder inhalation.
    Drugs R D; 2004; 5(3):162-3. PubMed ID: 15139778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.
    Sommerfeld M; Cui Y; Schmalfuß S
    Eur J Pharm Sci; 2019 Feb; 128():299-324. PubMed ID: 30553814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparison of Short-Term Growth During Treatment with Two Dry Powder Combinations of Inhaled Corticosteroids and Long-Acting β₂-Agonists.
    Wolthers OD; Shah T
    J Aerosol Med Pulm Drug Deliv; 2015 Jun; 28(3):182-8. PubMed ID: 25166221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Abbreviated Impactor Measurements (AIM) and Efficient Data Analysis (EDA) for Dry Powder Inhalers (DPIs) Against the Full-Resolution Next Generation Impactor (NGI).
    Mohan M; Lee S; Guo C; Peri SP; Doub WH
    AAPS PharmSciTech; 2017 Jul; 18(5):1585-1594. PubMed ID: 27624069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proposed algorithm for healthcare professionals based on product characteristics and in vitro performances in different use conditions using formoterol-based marketed products for inhalation.
    Wauthoz N; Hennia I; Dejaeger B; Ecenarro S; Amighi K
    Int J Pharm; 2017 Sep; 530(1-2):415-429. PubMed ID: 28757256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.
    Dahl R; Creemers JP; Van Noord J; Sips A; Della Cioppa G; Thomson M; Andriano K; Kottakis J; Fashola T
    Respiration; 2004; 71(2):126-33. PubMed ID: 15031566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
    Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G
    Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.